Rating Change
HC Wainwright & Co. reiterated its Buy rating on Actuate Therapeutics Inc (NASDAQ:ACTU) on August 18, 2026.
reiterateNASDAQ:ACTU
HC Wainwright & Co. Reiterates Buy Rating on Actuate Therapeutics Inc (ACTU)
HC Wainwright & Co. reiterated its Buy rating on Actuate Therapeutics Inc (NASDAQ:ACTU) on August 18, 2026.
At publication ·
What changed
Actuate Therapeutics Inc (NASDAQ:ACTU) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $1.05
- Market capitalization
- $86.9M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Actuate Therapeutics (ACTU) on August 18, 2026, with the stock trading at $1.05 and a market capitalization of $86.9 million.
Market Context
Actuate Therapeutics Inc operates in the Healthcare sector. The stock currently trades at $1.05 with a market capitalization of $86.9M. The stock has declined 87.1% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Actuate Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Actuate Therapeutics Inc
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 30, 2026 | Rodman & Renshaw | Buy | N/A |
| May 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 22, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 13, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ACTU Stock Page
Frequently Asked Questions
What does the Buy rating mean for ACTU?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Actuate Therapeutics Inc (NASDAQ:ACTU). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ACTU forecast page.